• FDA’s New ‘Project Patient Voice’ to Share Symptoms Data From Cancer Trials
  • Ipatasertib Combo Fares Well in Early Results of IPATential150 Phase 3 Study
  • Relugolix Granted FDA Priority Review as New Treatment Type
  • Recommendation Against PSA Routine Screening May Have Contributed to Higher Rates of Advanced PC
  • Veyonda Aids Radiation Therapy in Reaching Distant Lesions in Late-stage Cancer Trial
  • Cancer DNA Levels in Blood Can Predict Treatment Responses
  • Xtandi Plus ADT Bolsters Survival in High-risk Patients, Phase 3 Trial Finds
  • U.K. Study to Examine Genetic Screening for Large Prostate Cancer Population
  • NHS England Offers Xtandi, Zytiga to New PC Patients During COVID-19 Pandemic
  • ADT May Protect Prostate Cancer Patients from COVID-19, Study Suggests
  • Updated Guidelines Recommend Rubraca for Some Prostate Cancer Patients
  • Rubraca Receives Conditional FDA Approval for metastatic CRPC Patients with BRCA Mutations